Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Novel nonapeptide GLP (28-36) amide derivatives with improved hypoglycemic and body weight lowering effects.

Li L, Wu L, E X, Yan W, Cai X, Han J, Sun L.

Bioorg Med Chem. 2019 Apr 15;27(8):1670-1676. doi: 10.1016/j.bmc.2019.03.014. Epub 2019 Mar 7.

PMID:
30878191
2.

GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

Taing MW, Rose FJ, Whitehead JP.

Drug Des Devel Ther. 2014 Jun 3;8:677-88. doi: 10.2147/DDDT.S35723. eCollection 2014. Review.

3.

GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.

Tomas E, Wood JA, Stanojevic V, Habener JF.

Regul Pept. 2011 Aug 8;169(1-3):43-8. doi: 10.1016/j.regpep.2011.04.006. Epub 2011 May 4.

PMID:
21549160
4.

Novel Pentapeptide GLP-1 (32-36) Amide Inhibits β-Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice.

Sun L, Dai Y, Wang C, Chu Y, Su X, Yang J, Zhou J, Huang W, Qian H.

Chem Biol Drug Des. 2015 Dec;86(6):1482-90. doi: 10.1111/cbdd.12615. Epub 2015 Aug 3.

PMID:
26178446
5.

GLP-1(28-36)amide, a Long Ignored Peptide Revisited.

Zhou B, Ji K, Peng A, Yang X, Huang K.

Open Biochem J. 2014 Dec 31;8:107-11. doi: 10.2174/1874091X01408010107. eCollection 2014.

6.

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR.

J Endocrinol. 2004 Mar;180(3):379-88.

PMID:
15012592
7.

GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.

Shao W, Wang Z, Ip W, Chiang YT, Xiong X, Chai T, Xu C, Wang Q, Jin T.

Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1263-72. doi: 10.1152/ajpendo.00600.2012. Epub 2013 Apr 9.

8.

GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.

Tomas E, Stanojevic V, Habener JF.

Regul Pept. 2011 Apr 11;167(2-3):177-84. doi: 10.1016/j.regpep.2011.01.003. Epub 2011 Jan 21.

PMID:
21256872
9.

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, Voigt K.

Regul Pept. 1995 Aug 22;58(3):149-56.

PMID:
8577927
10.

GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice.

Ip W, Shao W, Chiang YT, Jin T.

Am J Physiol Endocrinol Metab. 2013 Dec 1;305(11):E1348-58. doi: 10.1152/ajpendo.00376.2013. Epub 2013 Oct 1.

11.

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.

Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ.

Diabetologia. 1998 Mar;41(3):271-8.

PMID:
9541166
12.

A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.

Zhou J, Cai X, Huang X, Dai Y, Sun L, Zhang B, Yang B, Lin H, Huang W, Qian H.

Eur J Med Chem. 2017 Sep 29;138:1158-1169. doi: 10.1016/j.ejmech.2017.07.046. Epub 2017 Jul 24.

PMID:
28772236
13.

A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus.

Bai X, Niu Y, Zhu J, Yang AQ, Wu YF, Ye XS.

Bioorg Med Chem. 2016 Mar 15;24(6):1163-70. doi: 10.1016/j.bmc.2016.01.036. Epub 2016 Feb 12.

PMID:
26895657
14.

GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.

Guglielmi V, Sbraccia P.

Eat Weight Disord. 2017 Jun;22(2):231-240. doi: 10.1007/s40519-016-0352-y. Epub 2016 Dec 31. Review.

PMID:
28040864
15.

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

Biol Chem. 2003 Dec;384(12):1543-51.

PMID:
14719796
16.
17.

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.

Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, Jansson-Löfmark R, Naylor J, Rossi A, Bednarek MA, Bhagroo N, Salari H, Will S, Oldham S, Hansen G, Feigh M, Klein T, Grimsby J, Maguire S, Jermutus L, Rondinone CM, Coghlan MP.

Diabetes Obes Metab. 2016 Dec;18(12):1176-1190. doi: 10.1111/dom.12735. Epub 2016 Aug 15.

19.

Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.

Parthsarathy V, Hogg C, Flatt PR, O'Harte FPM.

Diabetes Obes Metab. 2018 Feb;20(2):319-327. doi: 10.1111/dom.13068. Epub 2017 Aug 22.

PMID:
28730728
20.

Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.

Sun L, Huang X, Han J, Cai X, Dai Y, Chu Y, Wang C, Huang W, Qian H.

Biochem Pharmacol. 2016 Jun 15;110-111:80-91. doi: 10.1016/j.bcp.2016.04.016. Epub 2016 May 4.

PMID:
27155328

Supplemental Content

Support Center